GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new ...
Full year 2025 revenue of $71.7 million, up 40%Record full-year operating cash flow of $13.1 million, up 60%Board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results